Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 12/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 11/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.49 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4318199 | 0.94 | OPRM1 (0.53) | OPRL1OPRM1OPRD1OPRK1BDKRB2 | |
| SCHEMBL4322675 | 0.91 | OPRM1 (0.51) | OPRL1OPRM1OPRD1OPRK1BDKRB2 | |
| SCHEMBL4330963 | 0.90 | OPRM1 (0.52) | OPRL1OPRM1OPRD1OPRK1MEN1 | |
| SCHEMBL4327419 | 0.90 | OPRM1 (0.50) | OPRL1OPRM1OPRD1OPRK1BDKRB2 | |
| SCHEMBL4326521 | 0.90 | MEN1 (0.51) | OPRL1OPRM1OPRD1OPRK1MEN1 | |
| SCHEMBL4338350 | 0.88 | MEN1 (0.49) | OPRL1OPRM1OPRD1OPRK1MEN1 | |
| SCHEMBL4330043 | 0.87 | OPRM1 (0.51) | OPRL1OPRM1OPRD1OPRK1MEN1 | |
| SCHEMBL4329472 | 0.86 | OPRL1 (0.55) | OPRL1OPRM1OPRD1OPRK1BDKRB2 | |
| SCHEMBL13914015 | 0.84 | DRD2 (0.55) | OPRL1OPRM1OPRD1OPRK1BDKRB2 | |
| SCHEMBL4329074 | 0.84 | MEN1 (0.49) | OPRL1OPRM1OPRD1OPRK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | OPRL1 96/4885OPRM1 264/4885OPRD1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.